Brain AVM drug trial pulled before it began

NCT ID NCT06098872

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This pilot study aimed to see if the oral drug trametinib could improve the structure of brain arteriovenous malformations (AVMs) in adults before their scheduled surgery. The goal was to shrink the AVM or reduce risky features. However, the trial was withdrawn before enrolling any participants, so no results are available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Trametinib (oral tablet)

What this could lead to

If it had worked, trametinib might have made brain AVMs smaller or safer before surgery, potentially reducing surgical risks.

What could go wrong

The study was withdrawn before any participants were enrolled, so no data exist. Even if conducted, it was a small pilot with no guarantee of benefit.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ARTERIOVENOUS MALFORMATIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

arteriovenous hemangioma/malformation arteriovenous malformations of the brain

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University Health Network

    Toronto, Ontario, Canada